We passionately improve health

Boehringer Ingelheim is a global, research-driven pharmaceutical company embracing many cultures and diverse societies.

THERAPEUTIC AREA

Cardiovascular

Cardiovascular disease

including

heart disease

and stroke

is a major
global health concern and the leading cause of death and disability worldwide¹

Cardiovascular disease, including heart disease and stroke, is a major global health concern and the leading cause of death and disability worldwide¹. At Boehringer Ingelheim we address unmet medical need by providing innovative treatments that improve the care of patients suffering from a range of cardiovascular conditions including irregular heartbeat (atrial fibrillation), stroke, blood clots in deep veins or lungs (deep vein thrombosis or pulmonary embolism), high blood pressure (hypertension) or heart attack (myocardial infarction).

¹ Vilahur G et al. Eur Heart J Suppl 2014; 16(Suppl_A): A7-A11.

Learn more

Metabolic

2.3

million people

About 2.3 million people in South Africa were living with type 2 diabetes in 2015 accounting for 7% of the population.>

About 2.3 million people in South Africa were living with type 2 diabetes in 2015 accounting for 7% of the population. This number is projected to increase to 4 million by 2035, a 55% increase in prevalence, the biggest driver being obesity. Type 2 diabetes is a chronic, progressive condition and long term complications include strokes, heart attack, and cardiovascular death, as well as diabetic kidney disease, retinopathy, arm and leg amputation, and autonomic neuropathy. In addition to the now marketed products from our own R & D we are also focussed cardio-metabolic indications with a high unmet medical need. Learn more